Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model
Molecules · 2024
DOI: 10.3390/molecules29112676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Rawiwan Wongnak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Life Science, Faculty of Engineering, Tokyo University of Agriculture and Technology, Nakamachi 2-24-16, Tokyo 184-85…. Hauptthemen laut MEDLINE: SARS-CoV-2, Spike Glycoprotein, Coronavirus, Antibodies, Neutralizing, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency, Institute for Fostering Leadership to create future value through Outstanding Research, Innova-tion and Sustainable Higher education (FLOuRISH).
Abstract (Originalsprache)
The Omicron BA.5 variant of SARS-CoV-2 is known for its high transmissibility and its capacity to evade immunity provided by vaccine protection against the (original) Wuhan strain. In our prior research, we successfully produced the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein in an E. coli expression system. Extensive biophysical characterization indicated that, even without glycosylation, the RBD maintained native-like conformational and biophysical properties. The current study explores the immunogenicity and neutralization capacity of the E. coli-expressed Omicron BA.5 RBD using a mouse model. Administration of three doses of the RBD without any adjuvant elicited high titer antisera of up to 7.3 × 105 and up to 1.6 × 106 after a booster shot. Immunization with RBD notably enhanced the population of CD44+CD62L+ T cells, indicating the generation of T cell memory. The in vitro assays demonstrated the antisera’s protective efficacy through significant inhibition of the interaction between SARS-CoV-2 and its human receptor, ACE2, and through potent neutralization of a pseudovirus. These findings underscore the potential of our E. coli-expressed RBD as a viable vaccine candidate against the Omicron variant of SARS-CoV-2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology and Life Science, Faculty of Engineering, Tokyo University of Agriculture and Technology, Nakamachi 2-24-16, Tokyo 184-8588, Japan.
- Institute of Global Innovation Research, Tokyo University of Agriculture and Technology, Tokyo 183-8538, Japan.
- Center for Infectious Disease Epidemiology and Prevention Research, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-Cho, Fuchu-shi 183-8509, Japan.
- Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, University of Chittagong, Chittagong 4331, Bangladesh.
ORCID-Profile: Mami Oba, Md Din Islam, Hitoshi Takemae, Yutaka Kuroda
Förderung
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Institute for Fostering Leadership to create future value through Outstanding Research, Innova-tion and Sustainable Higher education (FLOuRISH)
- JSPS Grant-in-Aid for Scientific Research
- Institute of Global Innovation Research (GIR)
- JST Program on Open Innovation Platform with Enterprises
- Research Institutes and Academia (OPERA) Interdisciplinary Research Initiative
- Integrated Photon Science, Institute for Fostering Leadership
Zitieren
APA
Wongnak, R., Brindha, S., Oba, M., Yoshizue, T., Islam, M. D., Islam, M. M., Takemae, H., Mizutani, T., & Kuroda, Y. (2024). Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model. Molecules. https://doi.org/10.3390/molecules29112676
Vancouver
Wongnak R, Brindha S, Oba M, Yoshizue T, Islam MD, Islam MM, et al. Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model. Molecules. 2024. doi:10.3390/molecules29112676
BibTeX
@article{Wongnak2024,
author = {Wongnak, Rawiwan and Brindha, Subbaian and Oba, Mami and Yoshizue, Takahiro and Islam, Md Din and Islam, M Monirul and Takemae, Hitoshi and Mizutani, Tetsuya and Kuroda, Yutaka},
title = {Non-Glycosylated SARS-CoV-2 Omicron BA.5 Receptor Binding Domain (RBD) with a Native-like Conformation Induces a Robust Immune Response with Potent Neutralization in a Mouse Model},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29112676}
}
EUVIMED